Abstract:Rationale: Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics. Objective: The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks. Methods: Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N=2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms. Results: Among respondents who reported lifetime psychedelic use (n=613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders. Conclusions: Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.

Psychedelic Microdosing among Young Adults from Southern California

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use

Microdosing Psychedelics: Current Evidence From Controlled Studies

Psychedelic Drug Microdosing Practices: A Qualitative Online Exploration

Microdosing psychedelics in the treatment of ADHD and comorbid disorders

Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research

Less is more? A review of psilocybin microdosing

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study

Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study

Keeping the promise: a critique of the current state of microdosing research

Neural effects of psychedelics: Complexity the key word

Exploring the discourses around microdosing psychedelics within the r/microdosing online community

Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide

Psilocybin Exposures Reported to US Poison Centers: National Trends Over a Decade

Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey

Psychedelic risks and benefits: A cross-sectional survey study

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Psychedelic use and psychiatric risks